JP2023505189A5 - - Google Patents
Info
- Publication number
- JP2023505189A5 JP2023505189A5 JP2022533344A JP2022533344A JP2023505189A5 JP 2023505189 A5 JP2023505189 A5 JP 2023505189A5 JP 2022533344 A JP2022533344 A JP 2022533344A JP 2022533344 A JP2022533344 A JP 2022533344A JP 2023505189 A5 JP2023505189 A5 JP 2023505189A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- subject
- administration
- bumetanide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962943638P | 2019-12-04 | 2019-12-04 | |
| US62/943,638 | 2019-12-04 | ||
| PCT/US2020/063491 WO2021113775A1 (en) | 2019-12-04 | 2020-12-04 | Methods and compositions for treating edema refractory to oral diuretics |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023505189A JP2023505189A (ja) | 2023-02-08 |
| JP2023505189A5 true JP2023505189A5 (https=) | 2023-12-12 |
Family
ID=76209409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022533344A Pending JP2023505189A (ja) | 2019-12-04 | 2020-12-04 | 経口利尿薬に不応性の浮腫を処置するための方法及び組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US11123319B2 (https=) |
| EP (1) | EP4069222A4 (https=) |
| JP (1) | JP2023505189A (https=) |
| KR (1) | KR20220113436A (https=) |
| CN (1) | CN115023223A (https=) |
| AU (1) | AU2020397176A1 (https=) |
| BR (1) | BR112022010879A2 (https=) |
| CA (1) | CA3160278A1 (https=) |
| IL (1) | IL293429A (https=) |
| WO (1) | WO2021113775A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL293429A (en) | 2019-12-04 | 2022-07-01 | RESQ Pharmaceuticals LLC | Methods and preparations for the treatment of edema resistant to oral diuretics |
| JP2024520788A (ja) * | 2021-06-09 | 2024-05-24 | レスク ファーマシューティカルズ エルエルシー | 経口利尿薬に不応性の浮腫を処置するための皮下製剤及び方法 |
| CA3225946A1 (en) | 2021-07-16 | 2023-01-19 | Hubert Clemens Pellikaan | Aqueous bumetanide-containing liquid |
| AU2022425382A1 (en) * | 2021-12-30 | 2024-07-11 | Neuropro Therapeutics, Inc. | Pharmaceutical composition |
| CN115645363B (zh) * | 2022-10-31 | 2025-06-10 | 浙江普利药业有限公司 | 一种布美他尼注射液及其制备方法 |
| WO2026017600A1 (en) | 2024-07-15 | 2026-01-22 | Dripel B.V. | Aqueous bumetanide-containing liquid |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040105818A1 (en) | 2002-11-26 | 2004-06-03 | Alexza Molecular Delivery Corporation | Diuretic aerosols and methods of making and using them |
| EP2389371A4 (en) * | 2009-01-22 | 2012-09-12 | Neurotherapeutics Pharma Inc | ANALOGUES OF BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE AND TORSEMID, AND RELATED COMPOSITIONS AND METHODS OF USE |
| LT2523661T (lt) * | 2010-01-15 | 2017-08-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Nkcc inhibitoriai autizmo gydymui |
| DK2701684T3 (en) * | 2011-04-28 | 2017-09-18 | Platform Brightworks Two Ltd | Improved parenteral formulations of lipophilic pharmaceuticals and methods for their preparation and use |
| US20140128469A1 (en) * | 2011-05-10 | 2014-05-08 | Concert Pharmaceuticals Inc. | Deuterated n-butyl bumetanide |
| US20150239832A1 (en) * | 2012-09-04 | 2015-08-27 | Neuro Pro Therapeutics, Inc. | Analogs and prodrugs of loop diuretics, including bumetanide, furosemide and piretanide; compositions and methods of use |
| WO2015191473A1 (en) * | 2014-06-08 | 2015-12-17 | Autotelic Llc | Fixed dose combination for pain relief without edema |
| US20210163406A1 (en) * | 2018-04-06 | 2021-06-03 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Bumetanide Derivatives for the Therapy of Stroke and Other Neurological Diseases/Disorders Involving NKCCs |
| IL293429A (en) | 2019-12-04 | 2022-07-01 | RESQ Pharmaceuticals LLC | Methods and preparations for the treatment of edema resistant to oral diuretics |
| JP2024520788A (ja) | 2021-06-09 | 2024-05-24 | レスク ファーマシューティカルズ エルエルシー | 経口利尿薬に不応性の浮腫を処置するための皮下製剤及び方法 |
-
2020
- 2020-12-04 IL IL293429A patent/IL293429A/en unknown
- 2020-12-04 JP JP2022533344A patent/JP2023505189A/ja active Pending
- 2020-12-04 US US17/112,899 patent/US11123319B2/en active Active
- 2020-12-04 BR BR112022010879A patent/BR112022010879A2/pt unknown
- 2020-12-04 WO PCT/US2020/063491 patent/WO2021113775A1/en not_active Ceased
- 2020-12-04 CN CN202080090912.6A patent/CN115023223A/zh active Pending
- 2020-12-04 AU AU2020397176A patent/AU2020397176A1/en active Pending
- 2020-12-04 EP EP20896035.1A patent/EP4069222A4/en active Pending
- 2020-12-04 CA CA3160278A patent/CA3160278A1/en active Pending
- 2020-12-04 KR KR1020227022652A patent/KR20220113436A/ko active Pending
-
2021
- 2021-06-11 US US17/345,550 patent/US11260038B1/en active Active
-
2022
- 2022-02-25 US US17/680,591 patent/US12150923B2/en active Active
-
2024
- 2024-10-15 US US18/916,471 patent/US12329731B2/en active Active
-
2025
- 2025-05-14 US US19/208,335 patent/US12558330B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023505189A5 (https=) | ||
| US20230112834A1 (en) | Parenteral formulations of treprostinil | |
| JP2517293B2 (ja) | 細胞、組織修復剤 | |
| AU2007298814B2 (en) | Galenic form for the trans-mucosal delivery of active ingredients | |
| ES2244418T3 (es) | Composiciones de apomorfina y sidenalfilo y utilizacion de los mismos para el tratamiento de la disfuncion erectil. | |
| JPH013193A (ja) | 細胞、組織修復剤 | |
| JP4827725B2 (ja) | 医薬品組成物 | |
| JP2007532663A (ja) | ニューロパシー性の糖尿病性足潰瘍を治療するためのトレプロスチニルの使用 | |
| US20240269238A1 (en) | Therapeutic Regimens and Methods for Reducing Body Weight in a Subject with Fatty Liver Disease using a GLP-1R and GCGR Agonist | |
| US4789660A (en) | Insulin administration using methyl and propyl paraben | |
| US3922340A (en) | Pharmaceutical compositions for treating lung diseases | |
| JP6491191B2 (ja) | 咽喉炎、嗄声及び関連の空咳、並びに口腔及び咽頭腔の炎症性疾患の治療用ロゼンジ剤 | |
| WO2002024202A1 (en) | Nasal delivery of apomorphine in combination with glycol derivatives | |
| JP2024531685A5 (https=) | ||
| JP2024520788A5 (https=) | ||
| JP2012532852A (ja) | ２型糖尿病における食後高血糖の経頬粘膜治療の方法、および当該治療に用いられる医薬組成物 | |
| EA025203B1 (ru) | Фармацевтический состав для назального применения, содержащий флутиказон | |
| US20180344696A1 (en) | Synergistic combination of pyrrolidone carboxylic acid and/or salts thereof and hyaluronic acid and/or salts thereof, for use in the treatment and/or prevention of dryness and irritation of the mucosae, and related pharmaceutical formulations | |
| JP2577016B2 (ja) | 消化管疾患治療剤 | |
| WO2005049053A1 (en) | Composition comprising a magnesium compound and/or a magnesium saltfor improving sexual dysfunction | |
| CN108853093A (zh) | 局部给药型的吞咽障碍改善用药物 | |
| NZ201683A (en) | Pharmaceutical compositions comprising human proinsulin | |
| ES2938574T3 (es) | Péptido para la prevención o el tratamiento de la COVID-19 | |
| KR102832710B1 (ko) | 당뇨병 또는 당뇨합병증의 치료를 위한 4-헥실레조르시놀의 용도 | |
| EP1716887B1 (en) | Treatment of inclusion body myositis |